As the field of pulmonary hypertension expands, issues may arise where clinicians or scientists in the field desire additional guidance based on the currently available evidence, or in some cases, lack of published research on a particular subject. In those instances, PHA’s Scientific Leadership Council (SLC) convenes to analyze the issue, and from those interactions, Consensus Statements are developed.
The following statements on pulmonary hypertension medical issues were developed by the Education Committee of the SLC or its leadership, and were reviewed and approved by the SLC membership.
The SLC has also prepared Treatment Fact Sheets for information on specific PAH therapies.
PHA appreciates the work of the SLC's Education Committee in preparing and maintaining these documents. Originally developed by former Education Committee Chair, Ivan Robbins, MD, they are annually reviewed and updated (if necessary) by the SLC Education Committee.
To view Conflict of Interest Disclosures for Members of the SLC, see: Disclosures